UK biotech Adaptimmune raises $104m series A to build US-style company
This article was originally published in Scrip
Executive Summary
UK biotech company Adaptimmune, which signed a major deal with GlaxoSmithKline earlier this year, has raised $104m in a series A financing round from big-name US venture capital investors.